Cadena Elyse J, White David M, Kraguljac Nina V, Reid Meredith A, Lahti Adrienne C
Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Department of Psychology, University of Alabama at Birmingham, Birmingham, AL, USA.
NPJ Schizophr. 2018 May 7;4(1):8. doi: 10.1038/s41537-018-0051-y.
To understand the mechanism of cognitive control dysfunction in schizophrenia, it is critical to characterize brain function without the confounding effect of medication. It is also important to establish the extent to which antipsychotic medication restores brain function and whether those changes are related to psychosis improvement. Twenty-two patients with schizophrenia, initially unmedicated and after a 6-week course of risperidone, and 20 healthy controls (HC) studied twice, 6 weeks apart, performed an fMRI task. We examined group and longitudinal differences in anterior cingulate cortex (ACC), striatum, and midbrain functional activity during performance of a Stroop color task as well as activity patterns associated with improvement in psychosis symptoms. Unmedicated patients showed reduced functional activity in the ACC, striatum, and midbrain compared to HC. Post hoc contrasts from significant group-by-time interactions indicated that, in patients, drug administration was associated with both activity increases and decreases. In unmedicated patients, greater baseline functional activity in the striatum and midbrain predicted subsequent better treatment response. Greater changes in functional activity in ACC and ventral putamen over the course of 6 weeks positively correlated with better treatment response. Unmedicated patients show reduced activity in brain networks pivotal for cognitive control and medication is associated with functional changes in these regions. These results suggest a mechanism by which antipsychotic medication has a beneficial effect on cognition. Our results also support the notion that treatment response is determined by a combination of the baseline pattern of brain function and by the pharmacological modulation of these regions.
为了解精神分裂症认知控制功能障碍的机制,在不考虑药物混杂效应的情况下对脑功能进行特征描述至关重要。确定抗精神病药物恢复脑功能的程度以及这些变化是否与精神病症状改善相关也很重要。22名精神分裂症患者,最初未用药,在接受6周利培酮治疗后,以及20名健康对照者(HC),相隔6周进行了两次功能磁共振成像(fMRI)任务研究。我们检查了在执行Stroop颜色任务期间前扣带回皮质(ACC)、纹状体和中脑功能活动的组间和纵向差异,以及与精神病症状改善相关的活动模式。与HC相比,未用药患者的ACC、纹状体和中脑功能活动降低。来自显著的组×时间交互作用的事后对比表明,在患者中,药物给药与活动增加和减少均有关。在未用药患者中,纹状体和中脑较高的基线功能活动预示着随后更好的治疗反应。在6周的过程中,ACC和腹侧壳核功能活动的较大变化与更好的治疗反应呈正相关。未用药患者在对认知控制至关重要的脑网络中活动减少,药物治疗与这些区域的功能变化有关。这些结果提示了一种抗精神病药物对认知有有益作用的机制。我们的结果还支持这样一种观点,即治疗反应是由脑功能的基线模式和这些区域的药理调节共同决定的。